HTLV-1-associated myelopathy
GPTKB entity
Statements (48)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:HTLV-1_virus
|
| gptkbp:affects |
spinal cord
|
| gptkbp:associated_with |
HTLV-1 infection
|
| gptkbp:caused_by |
gptkb:HTLV-1_virus
|
| gptkbp:clinical_trial |
ongoing
investigating new therapies assessing biomarkers |
| gptkbp:complications |
paraplegia
neuropathic pain bladder dysfunction bowel dysfunction |
| gptkbp:current_use |
gptkb:T-cell_leukemia
tropical spastic paraparesis |
| gptkbp:demographics |
more common in women
|
| gptkbp:distribution |
gptkb:Africa
gptkb:Caribbean gptkb:Japan gptkb:South_America gptkb:United_States |
| gptkbp:healthcare |
gptkb:battle
|
| https://www.w3.org/2000/01/rdf-schema#label |
HTLV-1-associated myelopathy
|
| gptkbp:is_popular_in |
higher in certain regions
|
| gptkbp:premiered_on |
gradual
|
| gptkbp:public_awareness |
increased awareness needed
|
| gptkbp:research_focus |
immune response
genetic factors treatment efficacy epidemiology pathophysiology |
| gptkbp:risk_factor |
HTLV-1 transmission
|
| gptkbp:social_responsibility |
variable
progressive chronic clinical evaluation neurological examination MRI scan HTLV-1 serology |
| gptkbp:symptoms |
weakness
spasticity sensory disturbances |
| gptkbp:transmission |
breastfeeding
sexual contact blood transfusion |
| gptkbp:treatment |
physical therapy
symptomatic treatment antiviral therapy |